Maxim Shevtsov

Prof. Dr. Maxim Shevtsov

Center of Translational Cancer Research (TranslaTUM), Klinikum Rechts der Isar, Technical University Munich, 81675 Munich, Germany
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2016 in Frontiers in Immunology
Verified
Journal Article
Open access
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
Gabriele MulthoffGabriele Multhoff
Gabriele Multhoff
Intracellular residing heat shock proteins (HSPs) with a molecular weight of approximately 70 and 90 kDa function as molecular chaperones that assist folding/unfolding and transport of proteins across membranes and prevent protein aggregation after environmental stress. In contrast to normal cells, tumor cells have higher cytosolic HSP70 and Hsp90 levels which contribute to tumor cell propagation, metastasis and protection against apoptosis. In addition to their intracellular chaperoning functions, extracellular localized and membrane-bound HSPs have been found to play key roles in eliciting anti-tumor immune responses either by acting as carriers for tumor-derived, immunogenic peptides, as adjuvants for antigen presentation or as targets for the innate immune system. The interaction of HSP-peptide complexes or peptide-free HSPs with receptors on antigen presenting cells (APCs) promotes the maturation of dendritic cells (DCs), results in an up-regulation of MHC class I and class II molecules, induces secretion of pro- and anti-inflammatory cytokines, chemokines, and immune modulatory nitric oxides and thus integrate adaptive and innate immune phenomena. Herein, we aim to recapitulate the history and current status of HSP-based immunotherapies and vaccination strategies in the treatment of cancer.

19 March 2019 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
HSHiro Sato
Hiro Sato
GMGabriele Multhoff
Gabriele Multhoff
ASAtsushi Shibata
Atsushi Shibata
Radiotherapy (RT) has been applied for decades as a treatment modality in the management of various types of cancer. Ionizing radiation induces tumor cell death, which in turn can either elicit protective anti-tumor immune responses or immunosuppression in the tumor micromilieu that contributes to local tumor recurrence. Immunosuppression is frequently accompanied by the attraction of immunosuppressive cells such as myeloid-derived suppressor cells (MDSCs), M2 tumor-associated macrophages (TAMs), T regulatory cells (Tregs), N2 neutrophils, and by the release of immunosuppressive cytokines (TGF-β, IL-10) and chemokines. Immune checkpoint pathways, particularly of the PD-1/PD-L1 axis, have been determined as key regulators of cancer immune escape. While IFN-dependent upregulation of PD-L1 has been extensively investigated, up-to-date studies indicated the importance of DNA damage signaling in the regulation of PD-L1 expression following RT. DNA damage dependent PD-L1 expression is upregulated by ATM/ATR/Chk1 kinase activities and cGAS/STING-dependent pathway, proving the role of DNA damage signaling in PD-L1 induced expression. Checkpoint blockade immunotherapies (i.e., application of anti-PD-1 and anti-PD-L1 antibodies) combined with RT were shown to significantly improve the objective response rates in therapy of various primary and metastatic malignancies. Further improvements in the therapeutic potential of RT are based on combinations of RT with other immunotherapeutic approaches including vaccines, cytokines and cytokine inducers, and an adoptive immune cell transfer (DCs, NK cells, T cells). In the current review we provide immunological rationale for a combination of RT with various immunotherapies as well as analysis of the emerging preclinical evidences for these therapies.

1 January 2014 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
SHShevtsov
Shevtsov
BNBoris P Nikolaev
Boris P Nikolaev
LYLudmila Y Yakovleva
Ludmila Y Yakovleva
YMYaroslav Y Marchenko
Yaroslav Y Marchenko
AMAnastasiya L Mikhrina
Anastasiya L Mikhrina
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
Superparamagnetic iron oxide nanoparticles (SPIONs) conjugated with recombinant human epidermal growth factor (SPION–EGF) were studied as a potential agent for magnetic resonance imaging contrast enhancement of malignant brain tumors. Synthesized conjugates were characterized by transmission electron microscopy, dynamic light scattering, and nuclear magnetic resonance relaxometry. The interaction of SPION–EGF conjugates with cells was analyzed in a C6 glioma cell culture. The distribution of the nanoparticles and their accumulation in tumors were assessed by magnetic resonance imaging in an orthotopic model of C6 gliomas. SPION–EGF nanosuspensions had the properties of a negative contrast agent with high coefficients of relaxation efficiency. In vitro studies of SPION–EGF nanoparticles showed high intracellular incorporation and the absence of a toxic influence on C6 cell viability and proliferation. Intravenous administration of SPION–EGF conjugates in animals provided receptor-mediated targeted delivery across the blood–brain barrier and tumor retention of the nanoparticles; this was more efficient than with unconjugated SPIONs. The accumulation of conjugates in the glioma was revealed as hypotensive zones on T2-weighted images with a twofold reduction in T2 relaxation time in comparison to unconjugated SPIONs (P<0.001). SPION–EGF conjugates provide targeted delivery and efficient magnetic resonance contrast enhancement of EGFR-overexpressing C6 gliomas.

1 August 2021 in Biomaterials
Verified
Journal Article
Closed access
RXRou Xie
Rou Xie
SRShaobo Ruan
Shaobo Ruan
JLJiaqi Liu
Jiaqi Liu
LQLin Qin
Lin Qin
CYChuanyao Yang
Chuanyao Yang
YQYi Qin
Yi Qin

1 March 2018 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
BNBoris Nikolaev
Boris Nikolaev
YMYaroslav Marchenko
Yaroslav Marchenko
LYLudmila Yakovleva
Ludmila Yakovleva
NSNikita Skvortsov
Nikita Skvortsov
GMGabriele Multhoff
Gabriele Multhoff
Targeting experimental orthotopic glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs) Maxim Shevtsov,1–4 Boris Nikolaev,5 Yaroslav Marchenko,5 Ludmila Yakovleva,5 Nikita Skvortsov,5 Anton Mazur,6 Peter Tolstoy,6 Vyacheslav Ryzhov,7 Gabriele Multhoff2 1Department of Cell Biotechnology, Institute of Cytology of the Russian Academy of Sciences, St Petersburg, Russia; 2Department of Radiation Immuno Oncology, Technische Universität München, Klinikum rechts der Isar, Munich, Germany; 3Department of Biotechnology, Pavlov First Saint Petersburg State Medical University, St Petersburg, Russia; 4Department of Pediatric Neurosurgery, Polenov Russian Scientific Research Institute of Neurosurgery, St Petersburg, Russia; 5Department of Nanomedicine, Research Institute of Highly Pure Biopreparations, St Petersburg, Russia; 6Department of NMR, Saint Petersburg State University, St Petersburg, Russia; 7Department of NMR, NRC “Kurchatov Institute”, Petersburg Nuclear Physics Institute, Gatchina, Russia Background: Glioblastoma is the most devastating primary brain tumor of the central nervous system in adults. Magnetic nanocarriers may help not only for a targeted delivery of chemotherapeutic agents into the tumor site but also provide contrast enhancing properties for diagnostics using magnetic resonance imaging (MRI).Methods: Synthesized hybrid chitosan-dextran superparamagnetic nanoparticles (CS-DX-SPIONs) were characterized using transmission electron microscopy (TEM) and relaxometry studies. Nonlinear magnetic response measurements were employed for confirming the superparamagnetic state of particles. Following in vitro analysis of nanoparticles cellular uptake tumor targeting was assessed in the model of the orthotopic glioma in rodents.Results: CS-DX-SPIONs nanoparticles showed a uniform diameter of 55 nm under TEM and superparamagentic characteristics as determined by T1 (spin-lattice relaxation time) and T2 (spin-spin relaxation time) proton relaxation times. Application of the chitosan increased the charge from +8.9 to +19.3 mV of the dextran-based SPIONs. The nonlinear magnetic response at second harmonic of CS-DX-SPIONs following the slow change of stationary magnetic fields with very low hysteresis evidenced superparamagnetic state of particles at ambient temperatures. Confocal microscopy and flow cytometry studies showed an enhanced internalization of the chitosan-based nanoparticles in U87, C6 glioma and HeLa cells as compared to dextran-coated particles. Cytotoxicity assay demonstrated acceptable toxicity profile of the synthesized nanoparticles up to a concentration of 10 µg/ml. Intravenously administered CS-DX-SPIONs in orthotopic C6 gliomas in rats accumulated in the tumor site as shown by high-resolution MRI (11.0 T). Retention of nanoparticles resulted in a significant contrast enhancement of the tumor image that was accompanied with a dramatic drop in T2 values (P<0.001). Subsequent histological studies proved the accumulation of the nanoparticles inside glioblastoma cells.Conclusion: Hybrid chitosan-dextran magnetic particles demonstrated high MR contrast enhancing properties for the delineation of the brain tumor. Due to a significant retention of the particles in the tumor an application of the CS-DX-SPIONs could not only improve the tumor imaging but also could allow a targeted delivery of chemotherapeutic agents. Keywords: brain tumor, glioblastoma, tumor targeting, chitosan, superparamagnetic iron oxide nanoparticles, magnetic resonance imaging

20 May 2020 in Cells
Verified
Journal Article
Open access
PDF file
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
ZBZsolt Balogi
Zsolt Balogi
WKWilliam Khachatryan
William Khachatryan
huile gaohuile gao
huile gao
VLVigh László
Vigh László
Gabriele MulthoffGabriele Multhoff
Gabriele Multhoff
Heat shock proteins (HSPs) constitute a large family of conserved proteins acting as molecular chaperones that play a key role in intracellular protein homeostasis, regulation of apoptosis, and protection from various stress factors (including hypoxia, thermal stress, oxidative stress). Apart from their intracellular localization, members of different HSP families such as small HSPs, HSP40, HSP60, HSP70 and HSP90 have been found to be localized on the plasma membrane of malignantly transformed cells. In the current article, the role of membrane-associated molecular chaperones in normal and tumor cells is comprehensively reviewed with implications of these proteins as plausible targets for cancer therapy and diagnostics.